- In October 2023, Boston Scientific Corp. announced that it has received FDA approval for an expanded indication of its Wave Writer Alpha Spinal Cord Stimulator Systems. This approval allows for the treatment of painful diabetic peripheral neuropathy, a common complication of diabetes affecting the lower extremities. This advancement highlights Boston Scientific's commitment to addressing the needs of patients suffering from this debilitating condition
- On February 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Proclaim™ XR spinal cord stimulation system. This innovative technology is designed to treat painful diabetic peripheral neuropathy, a prevalent complication of diabetes. The approval underscores Abbott's dedication to enhancing treatment options for patients suffering from this challenging condition
- In January 2022, Medtronic announced that it received approval from the U.S. Food and Drug Administration for its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator. These devices are primarily intended for managing chronic pain, offering innovative solutions for patients seeking relief. This approval highlights Medtronic's commitment to advancing pain management technologies and improving patient outcomes
- In September 2021, Boston Scientific announced the European launch of its FAST therapy, a novel sub-perception treatment designed to provide significant pain relief within minutes. This innovative therapy enables quick assessment of treatment effectiveness, allowing patients to experience a rapid return to their quality of life. With its clinically proven benefits, FAST therapy represents a promising advancement in pain management solutions
